标题/作者	年份
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status YR Guo, QD Cao, ZS Hong, YY Tan, SD Chen, HJ Jin, KS Tan, DY Wang, ... Military medical research 7, 1-10	2020
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV TP Sheahan, AC Sims, SR Leist, A Schäfer, J Won, AJ Brown, ... Nature communications 11 (1), 222	2020
The epidemiology, diagnosis and treatment of COVID-19 P Zhai, Y Ding, X Wu, J Long, Y Zhong, Y Li International journal of antimicrobial agents 55 (5), 105955	2020
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir W Yin, C Mao, X Luan, DD Shen, Q Shen, H Su, X Wang, F Zhou, W Zhao, ... Science 368 (6498), 1499-1504	2020
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice TP Sheahan, AC Sims, S Zhou, RL Graham, AJ Pruijssers, ML Agostini, ... Science translational medicine 12 (541), eabb5883	2020
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus CJ Gordon, EP Tchesnokov, JY Feng, DP Porter, M Götte Journal of Biological Chemistry 295 (15), 4773-4779	2020
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency CJ Gordon, EP Tchesnokov, E Woolner, JK Perry, JY Feng, DP Porter, ... Journal of Biological Chemistry 295 (20), 6785-6797	2020
Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19 RT Eastman, JS Roth, KR Brimacombe, A Simeonov, M Shen, S Patnaik, ... ACS central science 6 (5), 672-683	2020
COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment A Parasher Postgraduate medical journal 97 (1147), 312-320	2021
COVID-19: Immunology and treatment options S Felsenstein, JA Herbert, PS McNamara, CM Hedrich Clinical immunology 215, 108448	2020
Structure of replicating SARS-CoV-2 polymerase HS Hillen, G Kokic, L Farnung, C Dienemann, D Tegunov, P Cramer Nature 584 (7819), 154-156	2020
Candidate drugs against SARS-CoV-2 and COVID-19 DL McKee, A Sternberg, U Stange, S Laufer, C Naujokat Pharmacological research 157, 104859	2020
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase AJ Brown, JJ Won, RL Graham, KH Dinnon III, AC Sims, JY Feng, T Cihlar, ... Antiviral research 169, 104541	2019
A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping M Romano, A Ruggiero, F Squeglia, G Maga, R Berisio Cells 9 (5), 1267	2020
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir G Kokic, HS Hillen, D Tegunov, C Dienemann, F Seitz, J Schmitzova, ... Nature communications 12 (1), 279	2021
Structural basis for RNA replication by the SARS-CoV-2 polymerase Q Wang, J Wu, H Wang, Y Gao, Q Liu, A Mu, W Ji, L Yan, Y Zhu, C Zhu, ... Cell 182 (2), 417-428. e13	2020
Arguments in favour of remdesivir for treating SARS-CoV-2 infections WC Ko, JM Rolain, NY Lee, PL Chen, CT Huang, PI Lee, PR Hsueh International journal of antimicrobial agents 55 (4), 105933	2020
The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms L Alanagreh, F Alzoughool, M Atoum Pathogens 9 (5), 331	2020
The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase J Lung, YS Lin, YH Yang, YL Chou, LH Shu, YC Cheng, HT Liu, CY Wu Journal of medical virology 92 (6), 693-697	2020
Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019 A Barlow, KM Landolf, B Barlow, SYA Yeung, JJ Heavner, CW Claassen, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (5 …	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。